ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, and Bristol-Myers Squibb Company today announced that the companies received a complete response letter from the U.S. FDA for the first-line squamous cell carcinoma of the head and neck (SCCHN) supplemental Biologics License Application for ERBITUX (cetuximab).
The details can be read here.
No comments:
Post a Comment